Efficacy and Impact of Tarlatamab on Clinical Practice

A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed extensive-stage small cell lung cancer (ES-SCLC). They highlight its improvements in overall and progression-free survival vs chemotherapy, framing it as a practice-changing therapy that delivers both efficacy and a manageable safety profile.

A panelist discusses how real-world applicability of these results supports broader integration into second-line treatment plans, particularly for patients with declining functional status.

A panelist discusses how tarlatamab represents a meaningful advance in the field, signaling a shift toward targeted, biomarker-driven approaches that could redefine patient outcomes in ES-SCLC.